Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis.

In addition, we analyzed BrMFS in the Luminal group according to GRP94 expression (Figure 2 C) and observed that GRP94 was overexpressed in tumors from patients with reduced BrMFS (HR = 3.58; 95% CI: 0.98–13.11; p = 0.054—Wald test), although this finding did not reach statistical significance either.

also in 111,027 other papers